Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BAY-293
Cat. No.:
OB0225LY-0035
Appearance:
Solid
Purity:
≥96%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
BAY-293 is a small molecule compound that inhibits the ERK (extracellular signal-regulated kinase) signaling pathway.
CAS No.:
2244904-70-7
Formula:
C25H28N4O2S
Formula Weight:
448.58
Specification
Relative Density:
1.218 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BAY-293 can be use as a cell-active SOS1 inhibitor to disrupt the KRAS-SOS1 interaction.
Library Information
Targets:
GTPase superfamily
Receptors:
SOS1; Raf; Ras
Pathways:
GPCR/G protein; MAPK
Plate Number:
AOCL-1
Plate Location:
d7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
110 mg/mL; 245.22 mM
